Citations

Clear

14 citation(s) found for "Shinde, R".

A106-09 Senescence in Down Syndrome Lung: Early and Rising
Belgacemi, R, Alam, I El, Hoarau, A P, Shinde, R, Rehan, A, Chung, E, Jendzjowsky, N, Ian, G, Deutsch, G H, Pabelick, C M, Prakash, Y, Danopoulos, S, Alam, D Al, Belgacemi, Randa , El-Alam, Imad, Hoarau, Antony, Rehan, Anika , Chung, Ella, Jendzjowsky, Nicholas Gregory , Pabelick, Christina M. , Danopoulos, Soula , Alam, D. Al

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5365 Get It

Abstract Rationale Respiratory disease is a major cause of mortality in Down syndrome (DS; trisomy 21, T21). DS is considered a progeroid syndrome, with elevated cellular senescence (SEN) and oxidative stress. Because SEN shapes organogenesis, its dysregulation may impair lung morphogenesis. We previously found SEN/SASP (senescence-associated secretory phenotype) abnormalities in prenatal human T21 lungs. Here, we test whether these alterations persist and change after birth. Methods We analyzed human lung single-nuclear RNA (snRNA-seq) datasets (prenatal and postnatal) to quantify epithelial and mesenchymal SEN/SASP signatures. Sex- and age-matched T21 and non-T21 prenatal and postnatal lungs were studied; fibroblasts were isolated as prenatal human lung fibroblasts (HFLF) and postnatal human lung fibroblasts (HLF). SEN/SASP were measured by RT-qPCR and immunofluorescence (IF) in tissue and HFLF/HLF. HFLF/HLF were assayed for SA-β-gal, oxidative stress (CellROX/MitoSOX), and Ca²+ dynamics (Fura-2 AM). 48h treatments with tunicamycin (1µM, SEN inducer), 4-phenylbutyrate (4-PBA, 2 mM, ER Stress inhibitor), or pyrroloquinoline quinone (PQQ, 20 μM, antioxidant) were performed on T21 and non-T21 HFLF/HLF. Conditioned media (CM) were collected after 48h from untreated cultures and then applied to cells of the opposite genotype for 24, 48, and 72h. Results Overall SEN profile was similar in epithelium and mesenchyme across ages, but pathway signatures differed. Epithelium shows an inflammatory SASP, while mesenchyme shows a less-inflammatory, remodeling/growth-factor SASP. These lineage patterns were more evident postnatally. Whole-tissue IF showed increased γ-H2AX and p21 in T21 vs non-T21 both prenatally and postnatally (p < 0.05). At baseline, T21 HFLF/HLF had higher CDKN1A, CDKN2A, TP53, CDKN2B, and SERPINE1 (p < 0.05; n = 5-6), with increased γ-H2AX/p21 IF (p < 0.01; n = 6), SA-β-gal (p < 0.05; n = 5-6), and ER/mitochondrial stress (p < 0.05; n = 5-6). Fura-2 AM showed greater Ca²+ release in T21 HFLF/HLF at baseline and after acetylcholine (10 μM, p < 0.01; n = 5). Mitochondrial-morphology genes (FIS1, DNM1L, MFN1) were elevated in T21 HFLF/HLF (p < 0.05; n = 6). In T21 HFLF, 4-PBA and PQQ each reduced SA-β-gal (p < 0.01; n = 6). In postnatal HLF, PQQ had the stronger effect (p < 0.05; n = 5). T21 CM induced progressively greater SEN/SASP over 24/48/72h in non-T21 cells (p < 0.05; n = 5-6), while non-T21 CM partially rescued T21-HLF phenotypes at 24h only (p < 0.05; n = 5-6). Conclusion These data indicate that lung senescence in T21 initiates in utero and intensifies after birth and reflects lineage-specific pathways. ER-stress-related mechanisms are more prominent prenatally, while mitochondrial/redox mechanisms are predominant postnatally. This evidence suggests age and lineage-dependent drivers of senescence that may help explain DS lung disease and highlight potential new mechanistic targets. This abstract is funded by: NIH/NHLBI
Electronic health record implementation: The people side of change
Borgwardt, Heidi L., Botz, Catherine T., Doppler, Julie M., Elthon, Brenda I., Hansen, Victoria P., Jasperson, Jan C., Keller, Jeffrey J. Larson, Martindale-Mathern, Sonia C., Reinschmidt, Karen J. , Shinde, Archana, Martindale-Mathern, Sonia C.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 4 | Issue: 1 | Pages: 7

10.69554/vxzn5716 Get It

Implementation of Epic as an integrated electronic health record and revenue cycle management system was the largest software implementation in the history of Mayo Clinic. It converged thousands of workflows, eliminated hundreds of legacy systems and affected thousands of end users across Mayo Clinic campuses. Strong physician leadership, project management and deliberate change management were important components in this US$1.5bn project. Mayo’s leadership used a distinctive approach to prepare staff to make these important changes. At the beginning of the project, leaders developed a deliberate and robust change management strategy and formed a team focused on change management and communications. The change management team comprised Mayo Clinic health systems engineers, who know healthcare and Mayo’s culture and values and have expertise in systems engineering and quality improvement principles. The team developed an approach using various tools to support operational readiness and change readiness and to communicate important messages throughout the project cycle. In this paper, crucial components of the project for successfully managing the people side of change are described: development of an approach to change management that fits the organisation, creation of a dynamic team with the right skills mix and execution of appropriate timing of tactics.
Change management: A framework for measuring and implementing organisational change
Leung, Christa Y., Barclay, Jason E., Botz, Catherine T., Hanf, Nicole K., Jasperson, Jan C., Kirby, Keri N., Mull, Christopher J., Shinde, Archana, Vogl, Matthew M.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 5 | Issue: 4 | Pages: 299

10.69554/ocdg9924 Get It

In 2018, Mayo Clinic completed the largest transformational project in its 150-year history. Mayo Clinic was prepared to take on the implementation of new software systems (Epic Systems Corp) as an integrated electronic health record (EHR) and revenue cycle management (RCM) system across all sites of the enterprise. Three foundational teams were launched for this project: leadership, project management and change management. In a project such as this, a common pitfall is to focus completely on the system and lose sight of the end users. For Mayo Clinic, the people side of change was at the forefront of the project. A robust change management team was budgeted, staffed and engaged with an experienced outside consulting partner. A goal for the change management team centred on the best way to measure the change management impact and the degree to which it was making a positive contribution in driving successful adoption of the new EHR and RCM system. With literature lacking in this area, the team moved forward with courage and quickly learned that the easy part was the development of a survey with questions mapped to the six components of the change management strategy and the phases of the awareness, desire, knowledge, ability, reinforcement (ADKAR) Model (Prosci Inc). The hard part was building the infrastructure to visually display millions of rows of data that needed to be positioned, filtered and analysed for all affected locations. The authors share the methods to measure change and explain the importance of developing a comprehensive and robust means of gathering and displaying large volumes of change management data at the project onset. This paper prepares the reader to confidently develop an organisational framework to measure and report the effectiveness of a change management strategy.
Barriers to successful change management
Bassi, Darshi, Shinde, Archana

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 8 | Issue: 3 | Pages: 271

10.69554/lfyy5730 Get It

Change management plays a crucial role in an organisation’s ability to adapt and thrive in today’s ever-evolving and fast-changing technologically enabled business landscape. Many organisations continue to struggle with effective change management, resulting in failed projects and missed opportunities for growth and development. This paper analyses the reasons why organisations frequently falter in change management efforts and provides insights into overcoming these barriers. The paper identifies a host of significant barriers to effective and successful change management. Each barrier is discussed in detail, explaining the negative effect it can have on change initiatives. Among these barriers are the lack of change management role accountability, a culture where change management is not embraced at all levels, a lack of change champions and leadership support, resistance to change, limited employee involvement, inadequate and poorly designed communications and a failure to properly integrate change management with other complementary approaches. The paper provides practical recommendations to overcome these barriers. It emphasises the crucial role of leadership in championing the change, communicating the vision and actively involving employees in the change process. It underscores the importance of a well-crafted, clear and consistent communication that can help build trust, ensure buy-in and reduce resistance. The paper also highlights the need for robust integration of change management with other complementary approaches. Furthermore, the paper underscores the significance of a centralised change management approach, incorporating tools, best practices and standardised change management practices, and setting realistic expectations to sustain change efforts over time. It stresses the need for organisations to provide the necessary resources, authority and support to staff to effectively fulfil their change management roles. In conclusion, this paper provides insights into overcoming the main barriers to successful change implementation. By implementing the suggested strategies, organisations can enhance their change management capabilities and increase their adaptability, thereby ensuring long-term success in a rapidly changing business landscape.
An implementation guide to improve accuracy and efficiency for outpatient referrals using EHR functionality
Shinde, Archana S., Nelson, Suzanne , Counselman, Shannon M., Mundell, William C., Nelson, Suzanne, Crum, Brian A.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 6 | Issue: 4 | Pages: 351

10.69554/kufm9404 Get It

Mayo Clinic adopted one electronic health record (EHR) across all 70 locations in five different states in 2017 and 18. A post-implementation review addressed concerns, and new workflows, processes and functionalities were adjusted. A common issue raised by multiple departments related to difficulty in accessing the right referral orders. Referrals between departments at Mayo Clinic are orders driven; scheduling is dependent on accurate ordering. Mayo Clinic’s vast size and number of specialties resulted in a very large catalogue of referral orders mapping to appointment types specific to each specialty. Providers found ordering in the new system time-consuming and looking for specific orders tedious. Often, wrong orders were selected, resulting in scheduling errors, reordering, rescheduling and staff and patient dissatisfaction. To solve this problem, an innovative functionality, EZ Panels, was created, which uses a panel-within-panel approach to group orders by speciality, displaying a much shorter list to providers. This functionality improved ordering capabilities, making it easier for providers to access the correct orders and make referrals accurately and efficiently. All 70 practices built and implemented EZ Panels in less than one year. Our fast-paced build and implementation approach can be modified and used by any healthcare system experiencing similar issues.
Estimation of Physiologic Pressures: Invasive and Non-Invasive Techniques, AI Models, and Future Perspectives
Manga, Sharanya, Muthavarapu, Neha, Redij, Renisha, Baraskar, Bhavana , Kaur, Avneet , Gaddam, Sunil , Gopalakrishnan, Keerthy, Shinde, Rutuja, Rajagopal, Anjali , Samaddar, Poulami , Damani, Devanshi N. , Shivaram, Suganti, Dey, Shuvashis , Mitra, Dipankar , Roy, Sayan , Kulkarni, Kanchan , Arunachalam, Shivaram P. , Arunachalam, S P , Dey, Shuvashis , Roy, Sayan , Kulkarni, Kanchan , Shivaram, Suganti

Mayo Clinic

Sensors | June 21, 2023 | Volume: 23 | Issue: 12 | Pages: 5744

10.3390/s23125744 | PMID 37420919 Get It

The measurement of physiologic pressure helps diagnose and prevent associated health complications. From typical conventional methods to more complicated modalities, such as the estimation of intracranial pressures, numerous invasive and noninvasive tools that provide us with insight into daily physiology and aid in understanding pathology are within our grasp. Currently, our standards for estimating vital pressures, including continuous BP measurements, pulmonary capillary wedge pressures, and hepatic portal gradients, involve the use of invasive modalities. As an emerging field in medical technology, artificial intelligence (AI) has been incorporated into analyzing and predicting patterns of physiologic pressures. AI has been used to construct models that have clinical applicability both in hospital settings and at-home settings for ease of use for patients. Studies applying AI to each of these compartmental pressures were searched and shortlisted for thorough assessment and review. There are several AI-based innovations in noninvasive blood pressure estimation based on imaging, auscultation, oscillometry and wearable technology employing biosignals. The purpose of this review is to provide an in-depth assessment of the involved physiologies, prevailing methodologies and emerging technologies incorporating AI in clinical practice for each type of compartmental pressure measurement. We also bring to the forefront AI-based noninvasive estimation techniques for physiologic pressure based on microwave systems that have promising potential for clinical practice.
BLOOD PRESSURE PREDICTION FROM PHOTOPLETHYSMOGRAM SIGNAL USING ARTIFICIAL INTELLIGENCE
Shinde, Rutuja, Manga, Manga, Muthavarapu, Neha, Gopalakrishnan, Keerthy, Aakre, Christopher A. , Ryu, Alexander J. , Arunachalam, S P , Ryu, Alexander J. , Arunachalam, Shivaram P.

Mayo Clinic

2023 Design of Medical Devices Conference | June 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2023-2769 Get It

Abstract Blood pressure measurement in current medical practice relies on manual methods with the most widely used modality being sphygmomanometers. Utilizing the principle of Photoplethysmography, it is possible to provide an accurate reading of one’s blood pressure through light signals and photodetector devices. This research paper introduces a new Artificial Intelligence driven approach to predict Blood pressure levels and classify them according to the updated ACC (American College of Cardiology) criteria as Normal, Elevated, Stage I, and II Hypertension from the given PPG signal values using Machine Learning Models. This research paper aims to accurately read the Systolic and Diastolic Blood Pressure using Artificial Intelligence, place them into the correct value bins and further prove that the blood pressure values differ based on different skin tones in different light wavelengths such as red, infrared, and green. Machine Learning models such as the Support Vector Machine have shown an accuracy of 70.58% for Systolic Blood Pressure and Decision Tree with an accuracy of 74.4% for Diastolic Blood Pressure classification. The models used in this research are Support Vector Machine, Decision Tree and K-Nearest Neighbor. This research study has future applications and extensions to predict blood pressure levels for patients with different skin tones under different light radiations and PPG signal readings. Neural Network models will be developed to compare the blood predictions from this work.
Mapping Keratoconus Molecular Substrates by Multiplexed High-Resolution Proteomics of Unpooled Corneas
Shinde, Vishal , Hu, Nan , Renuse, Santosh , Mahale, Alka, Pandey, Akhilesh , Stone, Donald U., Al-Swailem, Samar A. , Maktabi, Azza, Pandey, Akhilesh , Eberhart, Charles G. , Chakravarti, Shukti

Mayo Clinic

OMICS: A Journal of Integrative Biology | October 25, 2019 | Volume: 23 | Issue: 11 | Pages: 583-597

10.1089/omi.2019.0143 | PMID 31651220 Get It

Abstract Keratoconus (KCN) is a leading cause for cornea grafting worldwide. Keratoconus is a multifactorial disease that causes progressive thinning of the cornea and whose etiology is poorly understood. Several studies have used proteomics on patient tear fluids to identify potential biomarkers. However, proteome of the cornea itself has not been investigated fully. We report here new findings from a case–control study using multiplexed mass spectrometry (MS) on individual (unpooled) corneas to gain deeper insights into proteins and biomarkers relevant to keratoconus. We employed a high-pressure approach to extract total protein from individual corneas from five cases and five controls, followed by trypsin digestion and tandem mass tag (TMT) labeling. The MS-derived data were searched using the Human NCBI RefSeq protein database v92, with peptides and proteins filtered at 1% false discovery rate. A total of 3132 proteins were detected, of which 627 were altered significantly ( p ≤ 0.05) in keratoconus corneas. The increases were overwhelmingly in the mTOR/PI3/AKT signal-mediated regulations of cell survival and proliferation, nonsense-mediated decay of transcripts, and proteasomal pathways. The decreases were in several extracellular matrix proteins and in many members of the complement system. Importantly, this multiplexed proteomic study of keratoconus corneas identified, to our knowledge, the largest number of corneal proteins. The novel findings include changes in pathways that regulate transcript stability, proteasomal degradation, and the complement system in corneas with keratoconus. These observations offer new prospects toward future discovery of novel molecular targets for diagnostic and therapeutic innovations for patients with keratoconus.
Can pregabalin prevent paclitaxel-associated neuropathy?: A pilot trial.
Shinde, Shivani, Seisler, Drew K., Soori, Gamini S. , Atherton, Pamela J. , Pachman, Deirdre R. , Lafky, Jacqueline M., Ruddy, Kathryn J. , Loprinzi, Charles L.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9595-9595

10.1200/jco.2015.33.15_suppl.9595 Get It

Spleen Tyrosine Kinase–Mediated Autophagy Is Required for Epithelial–Mesenchymal Plasticity and Metastasis in Breast Cancer
Shinde, Aparna , Hardy, Shana D., Akhand, Saeed Salehin , Anderson, Joshua C. , Khodadadi, Ryan B. , Brown, Wells S. , George, Jason T. , Liu, Sheng , Wan, Jun , Levine, Herbert , Krusemark, Casey J. , Wendt, Michael K. , Anderson, Joshua C , Khodadadi, Ryan B , Willey, Christopher D , Wendt, Michael K , Wan, Jun , Kim, Dong Wook , Jolly, Mohit Kumar , Wang, Wen‐Hung , Geahlen, Robert L.

Mayo Clinic

Cancer Research | February 7, 2019 | Volume: 79 | Issue: 8 | Pages: 1831-1843

10.1158/0008-5472.can-18-2636 | PMID 30733195 Get It

Abstract The ability of breast cancer cells to transiently transition between epithelial and mesenchymal states contributes to their metastatic potential. Therefore, driving tumor cells into a stable mesenchymal state, as opposed to complete tumor cell eradication, presents an opportunity to pharmacologically limit disease progression by promoting an asymptomatic state of dormancy. Here, we compare a reversible model of epithelial–mesenchymal transition (EMT) induced by TGFβ to a stable mesenchymal phenotype induced by chronic exposure to the ErbB kinase inhibitor lapatinib. Only cells capable of returning to an epithelial phenotype resulted in skeletal metastasis. Gene expression analyses of the two mesenchymal states indicated similar transition expression profiles. A potently downregulated gene in both datasets was spleen tyrosine kinase (SYK). In contrast to this similar diminution in mRNA, kinome analyses using a peptide array and DNA-conjugated peptide substrates showed a robust increase in SYK activity upon TGFβ-induced EMT only. SYK was present in cytoplasmic RNA processing depots known as P-bodies formed during the onset of EMT, and SYK activity was required for autophagy-mediated clearance of P-bodies during mesenchymal–epithelial transition (MET). Genetic knockout of autophagy-related 7 (ATG7) or pharmacologic inhibition of SYK activity with fostamatinib, a clinically approved inhibitor of SYK, prevented P-body clearance and MET, inhibiting metastatic tumor outgrowth. Overall, this study suggests assessment of SYK activity as a biomarker for metastatic disease and the use of fostamatinib as a means to stabilize the latency of disseminated tumor cells. Significance: These findings present inhibition of spleen tyrosine kinase as a therapeutic option to limit breast cancer metastasis by promoting systemic tumor dormancy. See related commentary by Farrington and Narla, p. 1756